Caresfield LLC, a U.S.-based manufacturer and distributor of healthcare consumable products, is pleased to support the Cancer Research Institute (CRI) as a sponsor of Cancer Immunotherapy Month in June as part of the Caresfield Cares Program. CRI is a 501(c)(3) nonprofit organization funding immunotherapy research.
Caresfield CEO Ron Griffith is pleased to support CRI in this initiative because of how it aligns with Caresfield’s core values to work with a purpose and commit to caring.
“A number of our team members have been personally affected by cancer,” Griffith said. “As a company, Caresfield provides consumable products that help in the diagnosis and treatment of cancer, from the chemotherapy drug-rated nitrile exam gloves that clinicians wear to the healthcare labels that are used in specimen identification. By supporting Cancer Research Institute’s important purpose, we hope to help patients have the best chance for a longer life.”
“Caresfield and its employees are helping to transform the future of cancer treatment through their support of the Cancer Research Institute and our mission to save more lives by funding the most promising cancer immunotherapy research anywhere in the world,” said Jill O’Donnell-Tormey, Ph.D., CEO and Director of Scientific Affairs at the Cancer Research Institute. “During Cancer Immunotherapy Month in June, CRI celebrates Caresfield and all our partners who have joined us in spreading awareness of this revolutionary new way to treat—and one day potentially cure—all cancers.”
About Caresfield
Humanity in business is not a novel concept. At Caresfield, it’s the core of who we are. We’ve spent the last 30 years dedicated to providing healthcare facilities with the most responsive and humanized service in the industry. From our elevated customer care to our products that deliver exactly what you need, exactly when you need it. We see you; we hear you; we understand and we are here for you. Because humanity makes business better. Learn more about the Caresfield Cares program 2022 initiatives.
About the Cancer Research Institute
The Cancer Research Institute (CRI), established in 1953, is a highly rated U.S. nonprofit organization dedicated exclusively to saving more lives by fueling the discovery and development of powerful immunotherapies for all cancers. Guided by a world-renowned Scientific Advisory Council that includes four Nobel laureates and 27 members of the National Academy of Sciences, CRI has invested $474 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to cancerresearch.org and follow CRI on Twitter @CancerResearch.
